company background image
TNG

Transgene ENXTPA:TNG Stock Report

Last Price

€2.35

Market Cap

€233.5m

7D

-0.2%

1Y

-13.9%

Updated

23 May, 2022

Data

Company Financials +
TNG fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

TNG Stock Overview

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases.

Transgene Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Transgene
Historical stock prices
Current Share Price€2.35
52 Week High€3.15
52 Week Low€1.60
Beta0.87
1 Month Change-1.05%
3 Month Change8.55%
1 Year Change-13.92%
3 Year Change-20.34%
5 Year Change-29.43%
Change since IPO-94.78%

Recent News & Updates

Mar 18
Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?

Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

TNGFR BiotechsFR Market
7D-0.2%3.6%-1.5%
1Y-13.9%-39.9%-18.8%

Return vs Industry: TNG exceeded the French Biotechs industry which returned -39% over the past year.

Return vs Market: TNG underperformed the French Market which returned -5.4% over the past year.

Price Volatility

Is TNG's price volatile compared to industry and market?
TNG volatility
TNG Average Weekly Movement7.6%
Biotechs Industry Average Movement8.7%
Market Average Movement6.0%
10% most volatile stocks in FR Market10.2%
10% least volatile stocks in FR Market3.5%

Stable Share Price: TNG is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: TNG's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1979143Hedi Brahimhttps://www.transgene.fr

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.

Transgene Fundamentals Summary

How do Transgene's earnings and revenue compare to its market cap?
TNG fundamental statistics
Market Cap€233.52m
Earnings (TTM)-€19.54m
Revenue (TTM)€17.01m

13.7x

P/S Ratio

-12.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TNG income statement (TTM)
Revenue€17.01m
Cost of Revenue€32.88m
Gross Profit-€15.87m
Other Expenses€3.67m
Earnings-€19.54m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 07, 2022

Earnings per share (EPS)-0.20
Gross Margin-93.27%
Net Profit Margin-114.82%
Debt/Equity Ratio19.2%

How did TNG perform over the long term?

See historical performance and comparison

Valuation

Is Transgene undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


3.47x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TNG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TNG's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: TNG is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: TNG is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TNG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TNG is overvalued based on its PB Ratio (3.5x) compared to the FR Biotechs industry average (2.6x).


Future Growth

How is Transgene forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-27.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TNG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TNG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TNG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TNG's revenue is expected to decline over the next 3 years (-14.1% per year).

High Growth Revenue: TNG's revenue is forecast to decline over the next 3 years (-14.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TNG is forecast to be unprofitable in 3 years.


Past Performance

How has Transgene performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


10.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TNG is currently unprofitable.

Growing Profit Margin: TNG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TNG is unprofitable, but has reduced losses over the past 5 years at a rate of 10.6% per year.

Accelerating Growth: Unable to compare TNG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TNG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: TNG has a negative Return on Equity (-29.07%), as it is currently unprofitable.


Financial Health

How is Transgene's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TNG's short term assets (€62.2M) exceed its short term liabilities (€14.6M).

Long Term Liabilities: TNG's short term assets (€62.2M) exceed its long term liabilities (€20.0M).


Debt to Equity History and Analysis

Debt Level: TNG has more cash than its total debt.

Reducing Debt: TNG's debt to equity ratio has reduced from 117.8% to 19.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TNG has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TNG has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 6.5% each year.


Dividend

What is Transgene current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate TNG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TNG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TNG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TNG's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TNG has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.2yrs

Average management tenure


CEO

Hedi Brahim (40 yo)

1.33yrs

Tenure

€2,208,000

Compensation

Mr. Hedi Ben Brahim serves as the Chairman of the Board and Chief Executive Officer at Transgene SA since January 01, 2021. He serves as served as Director at ElsaLys Biotech SA until 2019. He has been Dir...


CEO Compensation Analysis

Compensation vs Market: Hedi's total compensation ($USD2.36M) is above average for companies of similar size in the French market ($USD385.78K).

Compensation vs Earnings: Insufficient data to compare Hedi's compensation with company performance.


Leadership Team

Experienced Management: TNG's management team is seasoned and experienced (6.2 years average tenure).


Board Members

Experienced Board: TNG's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.8%.


Top Shareholders

Company Information

Transgene SA's employee growth, exchange listings and data sources


Key Information

  • Name: Transgene SA
  • Ticker: TNG
  • Exchange: ENXTPA
  • Founded: 1979
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €233.519m
  • Shares outstanding: 99.37m
  • Website: https://www.transgene.fr

Number of Employees


Location

  • Transgene SA
  • 400, Boulevard Gonthier d’Andernach
  • Parc d’Innovation – CS80166
  • Illkirch-Graffenstaden
  • Alsace
  • 67405
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/23 00:00
End of Day Share Price2022/05/23 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.